The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 07, 2021

Filed:

Apr. 15, 2019
Applicant:

Curevac Ag, Tübingen, DE;

Inventors:

Mariola Fotin-Mleczek, Sindelfingen, DE;

Karl-Josef Kallen, Königsdorf, DE;

Jan C. Schmollinger, Munich, DE;

Assignee:

CureVac AG, Tübingen, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 39/39558 (2013.01); C07K 16/2878 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55516 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); Y02A 50/30 (2018.01);
Abstract

The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.


Find Patent Forward Citations

Loading…